Sierra Oncology
$15.889876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.
$15.88
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
-$0.14 (-0.88%) Today
+$0.06 (+0.38%) As of 1:00 PM UTC after-hours
Why Robinhood?
You can buy or sell SRRA and other stocks, options, and ETFs commission-free!
About SRRA
Sierra Oncology, Inc. Common Stock, also called Sierra Oncology, is a clinical stage drug development company of therapeutics for the treatment of cancer. The firm focuses on advancing targeted therapeutics for the treatment of patients with significant unmet medical needs in hematology and oncology. Its product Momelotinib, a selective and orally-bioavailable JAK1, JAK2 & ACVR1 inhibitor with a differentiated therapeutic profile in myelofibrosis encompassing robust constitutional symptom improvements. The company was founded on May 8, 2003 and is headquartered in Vancouver, Canada. The listed name for SRRA is Sierra Oncology, Inc. Common Stock.
CEO
Stephen George Dilly
Employees
71
Headquarters
Vancouver, British Columbia
Founded
2003
Market Cap
175.43M
Price-Earnings Ratio
—
Dividend Yield
—
Average Volume
59.11K
High Today
$15.98
Low Today
$15.65
Open Price
$15.95
Volume
10.62K
52 Week High
$16.92
52 Week Low
$8.55
Collections
SRRA Earnings
-$3.16
-$2.11
-$1.05
$0.00
Q2 FY19
Q3 FY19
Q4 FY19
Q1 FY20
Q2 FY20
Q3 FY20
Q4 FY20
Estimated
— per share
Actual
Expected Mar 2, Pre-Market